These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31315253)

  • 21. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets.
    Maltais AK; Stittelaar KJ; Veldhuis Kroeze EJ; van Amerongen G; Dijkshoorn ML; Krestin GP; Hinkula J; Arwidsson H; Lindberg A; Osterhaus AD
    Vaccine; 2014 May; 32(26):3307-15. PubMed ID: 24690149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucosal Vaccination for Influenza Protection Enhanced by Catalytic Immune-Adjuvant.
    Qin T; Ma S; Miao X; Tang Y; Huangfu D; Wang J; Jiang J; Xu N; Yin Y; Chen S; Liu X; Yin Y; Peng D; Gao L
    Adv Sci (Weinh); 2020 Sep; 7(18):2000771. PubMed ID: 32999833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physicochemical and immunological characterization of N,N,N-trimethyl chitosan-coated whole inactivated influenza virus vaccine for intranasal administration.
    Hagenaars N; Mastrobattista E; Verheul RJ; Mooren I; Glansbeek HL; Heldens JG; van den Bosch H; Jiskoot W
    Pharm Res; 2009 Jun; 26(6):1353-64. PubMed ID: 19224344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gold nanoparticles conjugating recombinant influenza hemagglutinin trimers and flagellin enhanced mucosal cellular immunity.
    Wang C; Zhu W; Luo Y; Wang BZ
    Nanomedicine; 2018 Jun; 14(4):1349-1360. PubMed ID: 29649593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
    Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
    mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Norovirus (NoV) specific protective immune responses induced by recombinant P dimer vaccine are enhanced by the mucosal adjuvant FlaB.
    Verma V; Tan W; Puth S; Cho KO; Lee SE; Rhee JH
    J Transl Med; 2016 May; 14(1):135. PubMed ID: 27184355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring Prime-Boost Vaccination Regimens with Different H1N1 Swine Influenza A Virus Strains and Vaccine Platforms.
    Parys A; Vandoorn E; Chiers K; Passvogel K; Fuchs W; Mettenleiter TC; Van Reeth K
    Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flagellin-expressing virus-like particles exhibit adjuvant effects on promoting IgG isotype-switched long-lasting antibody induction and protection of influenza vaccines in CD4-deficient mice.
    Ko EJ; Lee Y; Lee YT; Jung YJ; Ngo VL; Kim MC; Kim KH; Wang BZ; Gewirtz AT; Kang SM
    Vaccine; 2019 Jun; 37(26):3426-3434. PubMed ID: 31101421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.
    Wang D; Christopher ME; Nagata LP; Zabielski MA; Li H; Wong JP; Samuel J
    J Clin Virol; 2004 Dec; 31 Suppl 1():S99-106. PubMed ID: 15567101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucosal Immunity and Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs.
    Dhakal S; Renu S; Ghimire S; Shaan Lakshmanappa Y; Hogshead BT; Feliciano-Ruiz N; Lu F; HogenEsch H; Krakowka S; Lee CW; Renukaradhya GJ
    Front Immunol; 2018; 9():934. PubMed ID: 29770135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
    Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine.
    Patil HP; Murugappan S; ter Veer W; Meijerhof T; de Haan A; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A
    J Control Release; 2014 Jan; 174():51-62. PubMed ID: 24269505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
    Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
    J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal Immunization Using CTA1-DD as a Mucosal Adjuvant for an Inactivated Influenza Vaccine.
    Fan XT; Wang YL; Su QD; Qiu F; Yi Y; Jia ZY; Wang DY; Qin K; Zou YN; Bi SL; Shen LP
    Biomed Environ Sci; 2019 Jul; 32(7):531-540. PubMed ID: 31331437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Divergent immune responses and disease outcomes in piglets immunized with inactivated and attenuated H3N2 swine influenza vaccines in the presence of maternally-derived antibodies.
    Sandbulte MR; Platt R; Roth JA; Henningson JN; Gibson KA; Rajão DS; Loving CL; Vincent AL
    Virology; 2014 Sep; 464-465():45-54. PubMed ID: 25043588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The optimized fusion protein HA1-2-FliCΔD2D3 promotes mixed Th1/Th2 immune responses to influenza H7N9 with low induction of systemic proinflammatory cytokines in mice.
    Song L; Xiong D; Kang X; Jiao Y; Zhou X; Wu K; Zhou Y; Jiao X; Pan Z
    Antiviral Res; 2019 Jan; 161():10-19. PubMed ID: 30389471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvants.
    Samdal HH; Bakke H; Oftung F; Holst J; Haugen IL; Korsvold GE; Kristoffersen AC; Krogh G; Nord K; Rappuoli R; Berstad AK; Haneberg B
    Hum Vaccin; 2005; 1(2):85-90. PubMed ID: 17038826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced humoural and cellular immune responses to influenza H7N9 antigen HA1-2 fused with flagellin in chickens.
    Song L; Xiong D; Hu M; Kang X; Pan Z; Jiao X
    BMC Vet Res; 2017 Jun; 13(1):190. PubMed ID: 28637471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.